Literature DB >> 19034356

[Surveillance of Mycobacterium tuberculosis resistance to antituberculosis drugs].

María Consuelo Garzón1, Dailyn Yorledy Angée, Claudia Llerena, Dora Leticia Orjuela, Jorge Ernesto Victoria.   

Abstract

INTRODUCTION: Tuberculosis is an important cause of disease and death worldwide. An estimated 8.8 million new cases occurred in 2005 with 1.6 million deaths, including 195,000 among HIV-infected people. According to World Health Organization, the incidence rate was stable or in decline worldwide; however, the total number of new cases rose due to regional increases. Anti-TB drug resistance is a significant public health problem and an obstacle for its control worldwide. Therefore, measures must be taken for the adequate management of patients and the adoption of strategies to prevent TB dissemination.
OBJECTIVE: The prevalence of resistance of Mycobacterium tuberculosis was determined in untreated cases and in previously treated cases of pulmonary tuberculosis in Colombia.
MATERIALS AND METHODS: A cross-sectional study determined the prevalence of resistance of Mycobacterium tuberculosis to antituberculosis drugs in 1,189 untreated cases or previously treated cases of pulmonary tuberculosis between the years 2004 and 2005. Cultures were collected throughout the country for this one-year period. Drug susceptibility of the isolates was tested by the simplified variant of the Cannetti, Risk and Grooset multiple proportions technique.
RESULTS: The global resistance rate of 925 untreated patients was 11.8% (95% CI: 9-14%) and the rate of multidrug-resistant tuberculosis was 2.4% (95% CI: 1.6-3.6%). Among 264 previously treated patients, the rate of global resistance was 44.3% (95% CI: 38-50%) and that of multidrug resistance was 31.4% (95%CI: 26-37%).
CONCLUSIONS: When compared to previous studies, these data show that there has not been a significant increase in drug resistance. The findings indicate that the current treatment scheme provided by the National Tuberculosis Program is adequate.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19034356

Source DB:  PubMed          Journal:  Biomedica        ISSN: 0120-4157            Impact factor:   0.935


  4 in total

1.  The structural modeling of the interaction between levofloxacin and the Mycobacterium tuberculosis gyrase catalytic site sheds light on the mechanisms of fluoroquinolones resistant tuberculosis in Colombian clinical isolates.

Authors:  N Alvarez; E Zapata; G I Mejía; T Realpe; P Araque; C Peláez; F Rouzaud; J Robledo
Journal:  Biomed Res Int       Date:  2014-04-28       Impact factor: 3.411

2.  A molecular platform for the diagnosis of multidrug-resistant and pre-extensively drug-resistant tuberculosis based on single nucleotide polymorphism mutations present in Colombian isolates of Mycobacterium tuberculosis.

Authors:  Luz Maira Wintaco Martínez; Gloria Puerto Castro; Martha Inírida Guerrero
Journal:  Mem Inst Oswaldo Cruz       Date:  2016-02-02       Impact factor: 2.743

3.  Diagnosis and treatment of latent tuberculosis in patients with multiple sclerosis, expert consensus. On behalf of the Colombian Association of Neurology, Committee of Multiple Sclerosis.

Authors:  Carlos Navas; Carlos A Torres-Duque; Joe Munoz-Ceron; Carlos Álvarez; Juan R García; Luis Zarco; Lázaro A Vélez; Carlos Awad; Carlos Alberto Castro
Journal:  Mult Scler J Exp Transl Clin       Date:  2018-01-17

4.  ASAP1 gene polymorphisms are associated with susceptibility to tuberculosis in a Chinese Xinjiang Muslim population.

Authors:  Xianhua Wang; Aiguo Ma; Xiuxia Han; Aishan Litifu; Feng Xue
Journal:  Exp Ther Med       Date:  2018-01-25       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.